Nearly half of the children receiving intranasal midazolam for laceration repair in the emergency department (ED) exhibited extreme procedural anxiety. Younger age, reduced sociability, and extremity ...

Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, ...

AUSTIN, Texas — For acute seizure emergencies in children, intranasal midazolam is as safe and effective as intravenously or rectally administered diazepam, according to a systematic review of ...

Intranasal midazolam is an effective alternative to the oral version for children undergoing dental treatments, according to a new study. Researchers found that when dentists administered the drug ...

Intranasal (IN) midazolam was equally effective and showed comparable safety for the treatment of acute pediatric seizure emergencies as compared to intravenous (IV) or rectal diazepam, according to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Intranasal ...

Purpose: To predict midazolam absorption and pharmacokinetics (PK) after intranasal (i.n.) administration in young children. Methods: The absorption and PK of midazolam were simulated using ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

UCB said today it has acquired rights to Proximagen’s New Drug Application (NDA)-bound antiepilepsy candidate Midazolam Nasal Spray (USL261) for up to $370 million. Midazolam is being developed as a ...